Payment overview · 2025
General Payments
$276.50
11 reported records · 7 companies
Healthcare provider profile · identity verified
Mark S Romoff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VAN NUYS, CA · NPI 1578543179
Verified facts
What the public records show
CMS Open Payments records show Mark S Romoff, M.D. received $276.50 in general payments during 2025 across 11 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.28 | 41.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.70 | 18.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.61 | 9.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.84 | 9.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.38 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.53 | 7.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.16 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.80 | 9 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.28 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
43 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 573 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 57 |
| Alprazolam | Alprazolam | 176 | 56 |
| Jardiance | Empagliflozin | 144 | 44 |
| Losartan Potassium | Losartan Potassium | 138 | 39 |
| Metformin Hcl | Metformin Hcl | 132 | 42 |
| Furosemide | Furosemide | 131 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 38 |
| Simvastatin | Simvastatin | 129 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 27 |
| Ozempic | Semaglutide | 117 | 20 |
| Alendronate Sodium | Alendronate Sodium | 113 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 31 |
| Allopurinol | Allopurinol | 96 | 28 |
| Eliquis | Apixaban | 96 | 25 |
| Lisinopril | Lisinopril | 93 | 23 |
| Lorazepam | Lorazepam | 93 | 25 |
| Valsartan | Valsartan | 92 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 28 |
| Gabapentin | Gabapentin | 89 | 30 |
| Omeprazole | Omeprazole | 89 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 28 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Tramadol Hcl | Tramadol Hcl | 72 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 15 |
| Clonazepam | Clonazepam | 62 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Azithromycin | Azithromycin | 60 | 51 |
| Methylprednisolone | Methylprednisolone | 60 | 43 |
| Ezetimibe | Ezetimibe | 57 | 19 |
| Testosterone | Testosterone | 57 | 13 |
| Calcitriol | Calcitriol | 55 | 18 |
| Irbesartan | Irbesartan | 55 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 19 |
| Potassium Chloride | Potassium Chloride | 48 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Diazepam | Diazepam | 46 | 19 |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 42 |
| Atenolol | Atenolol | 42 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Nifedipine Er | Nifedipine | 42 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Famotidine | Famotidine | 40 | 17 |
| Sertraline Hcl | Sertraline Hcl | 40 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 12 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Meloxicam | Meloxicam | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ritalin | Methylphenidate Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.50 · 11 records | Boehringer Ingelheim Pharmaceuticals, Inc. | Cologuard Collection Kit, EVENITY, JARDIANCE, LEQVIO, NURTEC ODT, Ozempic, TRELEGY ELLIPTA, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error